Comment
(1)
Cfbuzlu/iStock via Getty Images
ADRs of Dr. Reddy's Laboratories (RDY) fell in the premarket on Thursday after the Indian drugmaker said that a product quality issue has forced it to delay the supplies of generics targeting Novo Nordisk’s (NVO) blockbuster GLP-1
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。